A comparison of the in vivo effects of ketotifen, clemastine, chlorpheniramine and sodium cromoglycate on histamine and allergen induced weals in human skin

British Journal of Clinical Pharmacology
M J PhillipsR J Davies

Abstract

The effect of ketotifen was compared with that of clemastine and chlorpheniramine, known antihistamines, and sodium cromoglycate, a drug considered to have mast cell "stabilizing' properties on histamine and allergen wealing reactions in human skin, in random order, double-blind, placebo controlled studies. Ketotifen was significantly more potent in the inhibition of both histamine (P less than 0.001) and allergen (P less than 0.001) skin wealing reactions than either clemastine or chlorpheniramine. Sodium cromoglycate had no significant effect on either histamine or allergen skin wealing reactions in any of the concentrations tested. However ketotifen, like clemastine, had a significantly greater inhibitory effect on histamine than on allergen induced weals (P less than 0.001) and both drugs were shown to act as competitive antagonists of histamine. Ketotifen has been shown to be a potent anti-histamine but there is no evidence from these in vivo studies to suggest that it has any additional inhibitory activity on release of mediators from mast cells in human skin.

References

Jan 1, 1973·The Journal of Allergy and Clinical Immunology·S P GalantH I Maibach
Jan 1, 1970·International Archives of Allergy and Applied Immunology·E S Assem, J L Mongar
Mar 1, 1971·The Journal of Clinical Pharmacology and New Drugs·A HedgesP Turner
Feb 1, 1980·The Journal of Allergy and Clinical Immunology·R P Harvey, A L Schocket
Aug 1, 1980·British Journal of Pharmacology·M K Church, C F Gradidge
Jan 1, 1982·International Archives of Allergy and Applied Immunology·I Moodley, R J Davies
Jan 1, 1981·British Journal of Diseases of the Chest·T C Stokes, J Morley
Mar 1, 1959·British Journal of Pharmacology and Chemotherapy·O ARUNLAKSHANA, H O SCHILD
Sep 1, 1960·British Journal of Pharmacology and Chemotherapy·I MOTA, W da SILVA
Sep 1, 1947·British Journal of Pharmacology and Chemotherapy·H O SCHILD

❮ Previous
Next ❯

Citations

Jan 1, 1989·Agents and Actions·J Morley, D Smith
Mar 1, 1992·Clinical and Experimental Allergy : Journal of the British Society for Allergy and Clinical Immunology·Y OkayamaM K Church
Apr 17, 2014·Naunyn-Schmiedeberg's Archives of Pharmacology·Edilson Dantas da Silva JúniorNeide H Jurkiewicz
Jan 1, 1988·European Journal of Clinical Pharmacology·F O MüllerG Groenewoud
Mar 1, 1985·Clinical Allergy·R Grönneberg, O Zetterström
Dec 1, 1988·British Journal of Clinical Pharmacology·J B WarrenC T Dollery
Oct 1, 1986·British Journal of Haematology·L M WilliamsonJ Fletcher
Jul 1, 1991·Clinical and Experimental Allergy : Journal of the British Society for Allergy and Clinical Immunology·C K LaiS T Holgate
Oct 1, 1994·Clinical and Experimental Allergy : Journal of the British Society for Allergy and Clinical Immunology·S A HamiltonR J Davies
Aug 5, 2009·Current Opinion in Allergy and Clinical Immunology·Alessandro LambiaseStefano Bonini
Feb 14, 2018·International Forum of Allergy & Rhinology·Sarah K WiseMark Zacharek

❮ Previous
Next ❯

Related Concepts

Related Feeds

Atopic Dermatitis

Atopic dermatitis is a chronic inflammatory genetically determined disease of the skin marked by increased ability to form reagin (IgE), with increased susceptibility to allergic rhinitis and asthma, and hereditary disposition to a lowered threshold for pruritus. Discover the latest research on atopic dermatitis here.